Triple Antithrombotic Therapy in Patients With Left Ventricular Assist Devices Article

Full Text via DOI: 10.1016/j.cpcardiol.2021.100940 Web of Science: 000836820600003

Cited authors

  • Krim SR, Bennett A, Pfeffer M, Campbell PT, Thai S, Baetz B, Wever-Pinzon J, Eiswirth C, Desai S, Ventura HO


  • Data on the efficacy and safety of the combination of warfarin and dual-antiplatelet therapy compared with warfarin and mono-antiplatelet therapy (MAPT) in patients with left ventricular assist devices (LVAD) remains scarce. Single-center study of 130 consecutive patients with durable LVAD. Baseline demographics, antithrombotic and antiplatelet regimen, and outcomes were compared between patients receiving warfarin plus dual-antiplatelet therapy (Group 1) and warfarin plus MAPT (Group 2). Antiplatelet therapy was assessed at hospital discharge post-LVAD implant and included aspirin, clopidogrel and dipyridamole. Outcomes at 1-year were assessed in each group. All patients were on aspirin and warfarin. No significant differences with regards to age, gender or ethnicity were noted at baseline between the two groups. Group 1 was more likely to have higher lactate dehydrogenase LDH levels at discharge and a history of stroke. No significant differences in international normalized ratio INR, hemoglobin or hematocrit were noted at discharge. During the study period, 48 patients had gastrointestinal bleeding events: 28 of 68 (41.2%) in Group 1 vs 20 of 62 (32.2%) in Group 2 (P = 0.293). At lyear, no statistically significant differences were noted in gastrointestinal bleeding (Group 1=27.90% vs Group 2 = 25.80, P = 0.784), ischemic stroke (Group 1= 8.8% vs group 2 = 6.5%, P = 0.612), hemorrhagic stroke (Group 1= 4.4% vs group 2 = 3.2%, P = 0.725) or mortality (Group 1= 5.9% vs Group 2 = 1.6%, P = 0.206). Rates of pump thrombosis however were lower in Group 1 (Group 1= 0% vs Group 2 = 6.5%, P = 0.033). Our study showed a high prevalence of triple-therapy antithrombotic use in LVAD patients with no significant differences in bleeding, stroke or survival. However, the risk for pump thrombosis was lower at 1-year when compared to patient receiving MAPT.

Publication date

  • 2022

Published in

International Standard Serial Number (ISSN)

  • 0146-2806

Number of pages

  • 10


  • 47


  • 8